Biosimilar Medication Formulary Updates
Sep. 2025Pharmacy Updates
Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
In ongoing efforts to improve the value and affordability of health care benefits for our members, UPMC Health Plan has implemented biosimilar medication formulary updates for denosumab, eculizumab, and ustekinumab products. Effective dates for these changes are as follows.
- UPMC for Life (Medicare/Special Needs Plan):
- Part D formularies effective Sept. 1, 2025
- Part B policies effective Sept. 10, 2025
- UPMC Health Plan (Commercial/Exchange) and UPMC for Kids (CHIP): Formularies effective Oct. 1, 2025
- UPMC for You and UPMC CHC: Effective Oct. 1, 2025
For full details on these changes, please refer to pages 18-19 in the September 2025 edition of Provider Partner Update.
Recent Announcements
Voluntary nationwide recall: Cyclobenzaprine (Unichem – August 2025)
Unichem Pharmaceuticals (USA), Inc. is recalling one lot, lot GMML24026A, of Cyclobenzaprine Hydrochloride Tablets USP 10 mg. Cyclobenzaprine is used for the relief of muscle spasms from certain conditions.Sep. 2025Pharmacy Updates
Voluntary nationwide recall: Lactated Ringers and 0.9% Sodium Chloride (B. Braun-Aug)
B. Braun Medical, Inc. is recalling two lots of Lactated Ringers Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL. These are intravenous (IV) fluids commonly used in the hospital to treat dehydration and other conditions.Aug. 2025Pharmacy Updates
CME Webinar: Evaluating Antimicrobial Stewardship Techniques in the Outpatient Setting
Please join us for a live, CME-accredited webinar on Tuesday, Nov. 4, from noon to 1 p.m. that will share an overview of evaluating antimicrobial stewardship techniques in the outpatient setting.Aug. 2025Education/Webinars